Related to EMA Road Map Aims to Stimulate Drug Development for Unmet Medical Needs and Rare and Neglected Diseases

• Regulatory Affairs: Spotlight on the FDA
  
• Point of View: Science and Technology Are Essential to Economic Recovery
  
• Feature Articles: Banked-Specimen Retrospective Studies
  
• Regulatory Affairs: Spotlight on the FDA
  
• Feature Articles: Choosing a Clinical Trial Disclosure System
  
• Spotlight on the FDA: Biosimilars and Follow-On Branded Biologics
  
• Point of View: Activism, Mendacity, and Pathological Science
  
• Spotlight on the FDA: Agency Gains Regulatory Clout
  
• Spotlight on the FDA: Update on Evolving Regulatory Guidance
  
• Spotlight on the FDA: Cracking Down on Misinformation
  
• Point of View: Pharma Innovation in Critical Condition
  
• Point of View: Medical Marijuana Policy Catches Up with Science
  
• Feature Articles: Expanded Access to Investigational Drugs
  
• Point of View: Whistle-Blower Protection a Must
  
• Point of View: Tempering Regulation with Common Sense
  
• Wall Street BioBeat: Big Pharma Reassesses Orphan Drug Sector
  
• Feature Articles: Oversight of Research Use Only Products
  
• Point of View: Cracking Open Genetic Privacy
  
• Legal Affairs: GINA's Impact on Life Science Research
  
• BioMarket Trends: Big Pharma Steps Into Orphan Drug Market